Ardelyx

Global Healthcare And Aging Trends Will Unleash Market Opportunity

AnalystConsensusTarget

Not Invested

Consensus Narrative from 11 Analysts

Published

27 Apr 25

Updated

15 Aug 25

AnalystConsensusTarget's Fair Value

US$11.18

45.4% undervalued

15 Aug

US$6.11

-3.8%

2.3%

Author's Valuation

US$11.2

45.4% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates1

Shared on01 May 25
Fair value Increased 2.50%

AnalystConsensusTarget Fair Value

US$11.2

45.4% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

19.83%

Biotech revenue growth rate

11.97%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.90%

Calculation

US$193.92m

Earnings '28

18.17x

PE Ratio '28

US$3.52b

Market Cap '28

US$3.52b

Market Cap '28

258.45m

No. shares '28

US$13.64

Share Price '28

US$13.64 Share Price '28

Discounted to 2025 @ 6.90% p.a.

US$11.16

Fair Value '25

Global Healthcare And Aging Trends Will Unleash Market Opportunity

Shared on01 May 25Fair value Increased 2.50%

Shared on01 May 25
Fair value Increased 2.50%